Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease

References

• Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol.30(12), 4807–4812 (2006).
   Google Scholar
• Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am. J. Physiol.273, 769–775 (1997).
   PubMedGoogle Scholar
• Papadakis KA, Targan SR. The role of chemokines and chemokine receptors in mucosal inflammation. Inflamm. Bowel Dis.6, 303–313 (2000).
   PubMedGoogle Scholar
• Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. Chemokines and the arrest of lymphocytes rolling underflow conditions. Science279, 381–384 (1998).
   PubMed Web of Science ®Google Scholar
• Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science272, 60–66 (1996).
   PubMed Web of Science ®Google Scholar
• Lee SC, Brummet ME, Shahabuddin S et al. Cutaneous injection of human subjects with macrophage inflammatory protein-1 α induces significant recruitment of neutrophils and monocytes. J. Immunol.164, 3392–3401 (2000).
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Sans M, Vetrano S et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J. Clin. Invest.117, 1951–1960 (2007).
   PubMed Web of Science ®Google Scholar
• Danese S, de la Motte C, Sturm A et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology124, 1249–1264 (2003).
   PubMed Web of Science ®Google Scholar
• Stefanelli T, Malesci A, De La Rue S, Danese S. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go. Autoimmunity Rev.7, 364–369 (2008).
   PubMed Web of Science ®Google Scholar
• Berlin C, Berg EL, Briskin MJ et al. α4 β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell74, 185–195 (1993).
   PubMed Web of Science ®Google Scholar
• Ley K. The role of selectins in inflammation and disease. Trends Mol. Med.9, 263–268 (2003).
   PubMed Web of Science ®Google Scholar
• Yoshida M, Gimbrone MA Jr. Novel roles for E-selectin in endothelial–leukocyte adhesion. Ann. NY Acad. Sci.811, 493–497 (1997).
   PubMedGoogle Scholar
• Cambien B, Wagner DD. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol. Med.10, 179–186 (2004).
   PubMed Web of Science ®Google Scholar
• Khan AI, Landis RC, Malhotra R. L-selectin ligands in lymphoid tissues and models of inflammation. Inflammation27265–280 (2003).
   PubMedGoogle Scholar
• Moore KL, Patel KD, Bruehl RE et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J. Cell Biol.128, 661–671 (1995).
   PubMed Web of Science ®Google Scholar
• Lasky LA, Singer MS, Dowbenko D et al. An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell69, 927–938 (1992).
   PubMed Web of Science ®Google Scholar
• Baumheter S, Singer MS, Henzel W et al. Binding of L-selectin to the vascular sialomucin CD34. Science262, 436–438 (1993).
   PubMed Web of Science ®Google Scholar
• Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function associated antigen 1 (LFA-1). Cell51, 813–819 (1987).
   PubMed Web of Science ®Google Scholar
• González-Amaro R, Mittelbrunn M, Sánchez-Madrid F. Therapeutic anti-integrin (α4 and αL) monoclonal antibodies: two-edged swords? Immunology116(3), 289–296 (2005).
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med.61, 35–47 (2010).
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Bank I. The role of very late antigen-1 in immune mediated inflammation. Clin. Immunol.113, 119–129 (2004).
   PubMedGoogle Scholar
• Strauch UG, Lifka A, Gosslar U, Kilshaw PJ, Clements J, Holzmann B. Distinct binding specificities of integrins α4 β7 (LPAM-1), α4 β1 (VLA-4), and α IEL β 7. Int. Immunol.6, 263–275 (1994).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N. Engl. J. Med.352, 2499–2507 (2005).
   PubMed Web of Science ®Google Scholar
• Hesterberg PE, Winsor-Hines D, Briskin MJ et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α 4 β 7. Gastroenterology.111(5), 1373–1380 (1996).
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther.330, 864–875 (2009).
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Sans M, Vetrano S et al. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur. J.Immunol.39, 290–300 (2009).
   PubMedGoogle Scholar
• Danese S, Fiorino G, Vetrano S et al. Infliximab inhibits mucosal pathological angiogenesis in Crohn’s disease. Presented at: Digestive Disease Week 2009. 30 May–4 June 2009, Chicago, IL, USA (Abstract T1687).
   Google Scholar
• Kent SJ, Karlik SJ, Cannon C et al. A monoclonal antibody to α 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol.58, 1–10 (1995).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn’s disease. N. Engl. J. Med.348, 24–32 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.353, 1912–1925 (2005).
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology132, 1627–1683 (2007).
   Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354, 924–933 (2006).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353, 362–368 (2005).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg G, Wild G et al. Efficacy and safety of a humanized anti α4β7 antibody in active Crohn’s disease (CD). Gastroenterology.124(Suppl. 1), A25–A26 (2003).
   Web of Science ®Google Scholar
• Fiorino G, Rovida S, Correale C, Danese S. Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner? Curr. Drug Targets11(2), 249–260 (2010).
   PubMedGoogle Scholar
• Wehner NG, Gasper C, Shopp G et al. Immunotoxicity profile of natalizumab. J. Immunotoxicol.6(2), 115–129 (2009).
   PubMed Web of Science ®Google Scholar
• Feagan B, Leach T, Milch C, Parikh A, Fox I. Emerging safety profile of vedolizumab: a novel, selective integrin inhibitor for treatment of IBD. Presented at: 5th Congress of ECCO. Prague, Czech Republic, 25–27 February 2010.
   Google Scholar
• Fedyk ER, Yang H, Wyant T et al. The pharmacologic and toxicologic profile of the gastrointestinal-selective, anti-inflammatory drug vedolizumab in cynomolgus macaques. Presented at: 5th Congress of ECCO. Prague, Czech Republic, 25–27 February 2010.
   Google Scholar
• Leung Y, Panaccione R. Anti-adhesion molecule strategies for Crohn disease. BioDrugs22, 259–264 (2008).
   PubMed Web of Science ®Google Scholar